‘Brightline-1’, comparing BI 907828 with doxorubicin in first-line treatment of patients with advanced dedifferentiated liposarcoma, will start recruiting in early 2022 (NCT05218499). The data ...

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with limited treatment options.

ROCHELLE PARK, NJ, UNITED STATES, December 4, 2024 /EINPresswire.com/ -- i3 Health ® and Oncology Data Advisor ® are pleased to announce the publication of the ...

Progression free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial. JAMA Oncol 2: 937-40, 2016.

Dalpiciclib is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Well Differentiated Liposarcoma.

The SU2C-SARC032 study demonstrated that pembrolizumab combined with radiotherapy and surgery was well tolerated, with ...

Progression free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: A phase 2 clinical trial. JAMA Oncol 2: 937-40, 2016.

However, 21 months ago, Amanda developed an extremely rare form of cancer called dedifferentiated liposarcoma. The ...